Erasca Receives FDA Clearance for First-in-Class Pan-KRAS Inhibitor, ERAS-4001, for Solid Tumors

Erasca Inc. (NASDAQ:ERAS) is one of the stocks under $10 to buy now. Earlier on June 2, Erasca announced that the US FDA had cleared its Investigational New Drug/IND application for ERAS-4001. This potential first-in-class and best-in-class pan-KRAS inhibitor is intended for the treatment of patients with KRAS-mutant (KRASm) solid tumors.

This clearance, along with that of ERAS-0015, which is a potential best-in-class pan-RAS molecular glue, occurred in May earlier this year, ahead of the company’s previously anticipated timeline. ERAS-4001 is designed to target multiple KRAS mutations as well as wild-type KRAS while sparing HRAS and NRAS, which could provide a better therapeutic window compared to broader pan-RAS inhibitors.

This differentiated approach aims to overcome treatment resistance to existing pan-RAS and mutant-selective KRAS inhibitors and address unmet needs for the estimated 2.2 million people diagnosed annually worldwide with KRASm tumors. Erasca anticipates disclosing initial Phase 1 monotherapy data for both ERAS-4001 and ERAS-0015 in 2026.

Erasca Inc. (NASDAQ:ERAS) is a clinical-stage precision oncology company that focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

While we acknowledge the potential of ERAS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.